{"id":"W3137610925","doi":"10.1016/s1470-2045(21)00005-x","title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Brentuximab vedotin; Pembrolizumab; Medicine; Interim analysis; Oncology; Internal medicine; Interim; Refractory (planetary science); Open label; Lymphoma; Hodgkin lymphoma; Clinical trial; Cancer; Immunotherapy; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008662121,0.0002965576,0.002212938,0.0002440863,0.00008267035,0.00004032594,0.0004795043,0.0001829696,0.000580889],"category_scores_gemma":[0.0007081621,0.0001865506,0.0001706399,0.001035994,0.0001706751,0.00008935191,0.0003303439,0.0002186855,0.00002362492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009851027,"about_ca_system_score_gemma":0.0009528421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005968799,"about_ca_topic_score_gemma":0.006125072,"domain_scores_codex":[0.9961922,0.001557494,0.0008108636,0.0006243112,0.0003227566,0.0004924035],"domain_scores_gemma":[0.9965598,0.001642416,0.0003601465,0.001088323,0.0001630052,0.0001862901],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6686434,0.141459,0.02049245,0.00005962866,0.007760671,0.006027664,0.006063816,0.00003349082,0.002480708,0.0001728204,0.001301564,0.1455048],"study_design_scores_gemma":[0.8747726,0.01935252,0.08423259,0.00007534974,0.00665741,0.00007013524,0.003517819,0.004157695,0.0008911499,0.00001085325,0.006027489,0.0002343762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938118,0.0004273477,0.000007448614,0.001887492,0.0003896302,0.001510339,0.00005485161,0.00003613673,0.001874949],"genre_scores_gemma":[0.997632,0.0002932406,0.0004980154,0.0006308595,0.0001752817,0.0003409085,0.0001555408,0.0000283661,0.0002457738],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2061292,"threshold_uncertainty_score":0.7607314,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1578634463106528,"score_gpt":0.4562258883862628,"score_spread":0.29836244207561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}